Efficacy of vitamin D supplementation in preventing peripheral neuropathy in multiple myeloma patients.

Withdrawn

• Conditions: neuralgia; 10025320; 10034606; Peripheral neuropathy

• Registration Number: NL-OMON43187
• Lead Sponsor: Medisch Centrum Leeuwarden

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 28 February 2024

Recruitment & Eligibility

• Status: Withdrawn
• Sex: Not specified
• Target Recruitment: 52

Inclusion Criteria

Patients with multiple myeloma with grade 2/3 peripheral neuropathy and a 25-hydroxyvitamin D level <75 nmol/l.

Exclusion Criteria

Contraindications for the use of vitamin D and/or patients who are already using any formulation of vitamin D

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The efficacy of vitamin D supplementation on the severity of PN in vitamin<br /><br>D-deficient MM patients with grade 2 or 3 PN. The main endpoint is the percent<br /><br>change in the number of patients whose PN decreases with at least 1 grade. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Secondary objectives are to assess an optimal dosing regimen of vitamin D<br /><br>supplementation in MM patients and to search for differences in the effect of<br /><br>vitamin D on PN for each drug.</p><br>